2 results
Approved WMOWill not start
To determine the performance of CardioFit* for the treatment of Class II-IV Heart Failure patients with preserved left ventricular function
Approved WMORecruiting
Primary• To evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first line treatment) as measured by Progression Free Survival (PFS) in subjects with Claudin (CLDN) 18.2-positive,…